NHIS and KIS face IPO sponsor bans in Korea

The Korea Exchange has temporarily banned NH Investment & Securities (NHIS) and Korea Investment & Securities (KIS) from sponsoring growth-track IPOs in the country until November 2020, according to multiple sources close to the situation.

  • By Gina Lee
  • 11 Jul 2019
The ban is a result of the regulator's July 5 decision to investigate US headquartered biopharmaceutical company Kolon TissueGene, which focuses on cell and gene therapy. It listed in Korea in October 2017. Kolon TissueGene, then referred to simply as TissueGene, raised W202.5bn ($178.9m) from its IPO, which ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Panda Bonds Top Arrangers

Rank Arranger Share % by Volume
1 Bank of China (BOC) 21.85
2 China Merchants Securities Co 14.67
3 Industrial and Commercial Bank of China (ICBC) 14.44
4 Agricultural Bank of China (ABC) 8.89
5 China Securities 7.41

Bookrunners of Asia-Pac (ex-Japan) ECM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 CITIC Securities 9,346.38 46 7.88%
2 Goldman Sachs 8,791.68 35 7.42%
3 Morgan Stanley 6,937.95 46 5.85%
4 China International Capital Corp Ltd 6,923.83 42 5.84%
5 UBS 6,281.96 46 5.30%

Bookrunners of Asia Pacific (ex-Japan) G3 DCM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 HSBC 20,690.46 181 8.39%
2 Citi 15,145.16 114 6.14%
3 JPMorgan 12,957.39 88 5.25%
4 Standard Chartered Bank 10,112.16 101 4.10%
5 Bank of China 9,370.02 117 3.80%

Asian polls & awards